Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease
There is provided a composition for anti-cancer or anti-inflammatory treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating disease by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3, its homologues, antibody to galectin-3 carbohydrate binding sites, or a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Further, there is provided a disease treatment having an effective amount of N-terminally truncated galectin-3 or its homologues, antibodies to galectin-3 carbohydrate binding sites, or a nucleic acid sequences encoding N-terminally truncated galectin-3 or its homologues, in a pharmaceutically acceptable carrier.
1 . A composition comprising an effective amount of N-terminally truncated galectin-3 and a pharmaceutically acceptable carrier.
2 . The composition according to claim 1 , wherein said N-terminally truncated galectin-3 has a sequence according to SEQ ID NO: 1 and analogues thereof.
3 . The composition according to claim 1 , wherein said N-terminally truncated galectin-3 is present in an amount sufficient to reduce tumor size.
4 . The composition according to claim 1 for use in for treating cancer.
5 . The composition according to claim 1 , wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.
6 . The composition according to claim 5 , wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.
7 . The composition according to claim 1 , wherein said composition in formulated for slow release.
8 . A method of treating a tumor in a patient by administering to a patient in need of treatment an effective amount of N-terminally truncated galectin-3 according to claim 1 , in a pharmaceutically acceptable carrier.
9 . The method according to claim 8 , wherein said administering step includes administering N-terminally truncated galectin-3 having a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.
10 . The method according to claim 9 , wherein said administering step includes administering analogues and homologues that include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.
11 . A treatment treatment for cancer and inflammation comprising an effective amount of N-terminally truncated galectin-3 according to claim 1 , and a pharmaceutically acceptable carrier.
12 . The treatment according to claim 11 , wherein said N-terminally truncated galectin-3 wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.
13 . The treatment according to claim 12 , wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.
14 . The treatment according to claim 11 , wherein said N-terminally truncated galectin-3 is present in an amount sufficient to prevent metastasis.
15 . An anti-cancer treatment comprising an effective amount of a nucleic acid sequence encoding an N-terminally truncated galectin-3 according to claim 1 , and a pharmaceutically acceptable carrier.
16 . The treatment according to claim 13 , wherein said nucleic acid sequence encoding the N-terminally truncated galectin-3 is present in an amount sufficient to prevent metastasis.
17 . The treatment according to claim 11 , wherein said treatment is formulated for slow release.
18 . A nucleic acid sequence encoding for an N-terminally truncated galectin-3.
19 . The nucleic acid sequence according to claim 18 , wherein said N-terminally truncated galectin-3 wherein said N-terminally truncated galectin-3 has a sequence as set forth in SEQ ID No:2 and analogues and homologues thereof.
20 . The nucleic acid sequences according to claim 19 , wherein said analogues and homologues include at least one set of polypeptides that include amino acid sequences of SEQ ID No:2 beginning with an amino acid residue from Try-63 through Arg-129 and extends at least to an amino acide residue from Asp-241 through Ile-250.
21 . A method of treating a tumor in a patient by administering to a patient in need of treatment an effective amount of a nucleic acid sequence encoding an N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.
22 . The method according to claim 21 , wherein said administering step includes administering the N-terminally truncated galectin-3 in a method selected from the group consisting essentially of intramuscularly, orally, intravenously, and locally.
23 . An antibody that specifically binds to carbohydrate ligands of galectin-3.
24 . The antibody according to claim 23 , wherein said antibody is used for treating cancer.